Tag: (NASDAQ:VBIV)
September 10, 2019
VBI Vaccines Announces Phase 2a Clinical Evaluation of VBI-1901
VBI Vaccines (NASDAQ:VBI) has announced a collaboration with GlaxoSmithKline (NYSE:GSK) to evaluate VBI’s VBI-1901 with GSK’s AS01 adjuvant system. As... May 1, 2019
VBI Vaccines Posts Q1 2019 Financial Results
VBI Vaccines reported its financial results for its Q1 ending March 31, 2019, and offered an update on the progress of... December 6, 2018
VBI Vaccines Enters into License and Collaboration Agreement with Brii Biosciences
VBI Vaccines (NASDAQ:VBIV) a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that it entered into... September 25, 2018
VBI Vaccines Announces Second Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma Patients
VBI Vaccines (NASDAQ:VBIV) a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the independent Data...
September 9, 2018